Novocare Wegovy now brings a free support membership and app together with the manufacturer's existing home-delivery route. Insured delivery and rewards points are announced additions. They aren't services everyone can use today. Wegovy still needs a prescription, and free membership doesn't mean free medicine.

Semaglutide is the medicine in Wegovy. It acts on GLP-1, a gut-hormone signal involved in appetite and blood sugar. Novocare is Novo Nordisk's program around its brand-name medicine.

Novocare Wegovy: what changed on November 17

As of November 20, 2026, the day this article was written, Novo's November 17 announcement describes a free membership combining a website, an app, coaching and progress tracking. Partners include WHOOP for health tracking, Berry Street for dietitian visits, Factor for meal delivery and Stitch Fix for styling. Their services have separate costs and eligibility rules.

The word “free” applies to joining. It doesn't mean that medicine, medical appointments or every partner service comes with the membership. A person looking for treatment information and someone filling a prescription are using different parts of the program.

The existing Wegovy home-delivery FAQ describes the prescription handoff: the prescriber sends it, the pharmacy processes it, and a text explains the account and payment steps. An existing prescription can also be transferred. A membership email isn't a pharmacy confirmation.

Someone expecting a refill still needs to know that the pharmacy has received and processed the prescription.

Novocare home delivery insurance: available versus planned

The current delivery program uses self-pay, meaning the patient pays outside insurance. Having insurance doesn't prevent someone from choosing that route. Using a cash program, however, doesn't turn the purchase into an insured prescription.

Novo's announcement places delivery for eligible commercially insured members and government-insured members, including Medicare Bridge, “in the coming weeks.” That is an announced expansion. The current Wegovy delivery FAQ still says it does not fill Medicare Bridge prescriptions at this time.

As of November 20, 2026, the day this article was written, Medicare's federal agency describes the Bridge as a temporary program for eligible Medicare prescription-plan members. It operates separately from Part D, Medicare's usual drug benefit, through December 31, 2027. Our Medicare GLP-1 coverage guide explains its eligibility rules.

An insurance offer on a website and insurance-paid home delivery answer different questions. Coverage still depends on the particular plan and prescription. Prior authorization means the insurer reviews medical information before agreeing to pay. A support program can help with paperwork without deciding the insurer's answer.

Novocare app and Novocare Points

The app belongs to the support membership. Rewards are a separate planned feature: “Later this year,” the release says, Novo plans to introduce Novocare Points, which would let eligible members earn through selected activities and use points toward participating partner offers. Earning rules and offers are due at launch; not every partner will participate.

A partner's presence in the app therefore doesn't establish that its services can be bought with points. Nor does the announcement establish a way to pay for Wegovy with rewards. Membership, a partner offer and medicine coverage each have their own terms.

Novocare vs LillyDirect: which medicine is involved?

Lilly runs its own channel for Zepbound, the brand containing tirzepatide, covered in our LillyDirect guide. These program names identify manufacturer channels. They don't decide which medicine suits someone's medical history, and a delivery preference doesn't establish a reason to switch medicines.

What the new program does not change

Support complements medical care. A clinician quoted in Novo's release describes it as something that can “complement, not replace” physician care. An app can't decide whether a symptom requires treatment or whether a prescription needs changing. Our semaglutide prescribing guide explains the medical review.

As of November 20, 2026, the day this article was written, Wegovy's official label from the U.S. Food and Drug Administration (FDA) carries “Revised: 06/2026.” It lists contraindications, meaning situations in which the medicine must not be used. These include a personal or family history of medullary thyroid carcinoma, a type of thyroid cancer, and MEN 2, an inherited condition affecting hormone-producing glands. A previous serious allergic reaction to semaglutide or the product's ingredients also rules out use. The label's boxed warning, its most prominent, concerns thyroid C-cell tumors: semaglutide caused them in rodents, and whether Wegovy causes them in humans is unknown.

The research concerns medical treatment, too. STEP 1, in the New England Journal of Medicine in 2021, studied 1,961 adults for 68 weeks with semaglutide or placebo, a treatment without the study medicine, plus lifestyle support. STEP 3, in JAMA in 2021, involved 611 adults and included 30 counseling visits alongside medicine or placebo. Neither trial tested the new Novocare membership, its app or its rewards.

What to watch as the program expands

The useful updates will be concrete: a start date for insured delivery, which prescriptions qualify, and the published points rules. Those details will show what a member can actually use, rather than what has been announced.

For someone arranging a refill, the practical questions remain who has the prescription, which payment route is being used, and whether processing is complete. Joining a membership alone doesn't confirm any of those steps. For brand payment terms, our semaglutide cost guide explains the separate routes.

A prescription conversation through Promise

Compounded means a pharmacy prepares a medication for a particular prescription. Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Wegovy is the brand-name product with FDA review; that review does not extend to compounded preparations. FDA explains that compounded drugs do not undergo its review for safety, effectiveness or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor.

At Promise, a licensed U.S. provider reviews every request and may prescribe or decline; not everyone qualifies.